(Q44416775)

2 December 2017

Progestin suppresses matrix metalloproteinase production in endometrial cancer (English)

1 reference

2 December 2017

3

1 reference

2 December 2017

Lisa A Di Nezza

1

1 reference

PubMed ID

12713999

2 December 2017

Tom Jobling

series ordinal

2

1 reference

PubMed ID

12713999

2 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

2 December 2017

1 reference

2 December 2017

89

1 reference

2 December 2017

2

1 reference

2 December 2017

325-333

1 reference

Uterine cancer (prevention)

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Two pathogenetic types of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Progesterone receptors in two groups of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Theories of endometrial carcinogenesis: a multidisciplinary approach

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Intrauterine progesterone treatment of early endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Estrogen use and cancer risk: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Estrogen and endometrial cancer: an epilogue à la recherche du temps perdu

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Molecular basis of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Cancer. Proteases--invasion and more.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Matrix metalloproteinase degradation of extracellular matrix: biological consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

How matrix metalloproteinases regulate cell behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Menstruation: induction by matrix metalloproteinases and inflammatory cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Mast cell regulation of human endometrial matrix metalloproteinases: A mechanism underlying menstruation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Tissue Inhibitors of Metalloproteinases in Endometrium of Ovariectomized Steroid-Treated Ewes and during the Estrous Cycle and Early Pregnancy1

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Expression of cytokeratin-20 in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Human breast cancer cell lines as models of growth regulation and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900089-1

7 January 2021

10.1016/S0090-8258(03)00089-1

Identifiers

DOI

1 reference

2 December 2017

1 reference

PubMed ID

12713999